{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096127","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.902530+00:00","generated_at":"2026-05-31T09:44:12.115110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024","bullets":["Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.","R&D expenses fell to $0.6M from $14.4M due to suspension of mavodelpar development and workforce cuts.","Merger with OnKure (all-stock) plus $65M PIPE expected to close H2 2024; combined cash ~$120M.","General and administrative expenses $5.8M vs $6.6M, with $2.4M increase in legal/advisory fees for merger."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096127","json":"https://secwatch.observer/filing/0000950170-24-096127.json","markdown":"https://secwatch.observer/filing/0000950170-24-096127.md","text":"https://secwatch.observer/filing/0000950170-24-096127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024096127/0000950170-24-096127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024096127/rphm-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:12.115110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}